Roche has officially announced that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc.. Under the established provisions, the two healthcare leaders will join forces to co-develop and co-commercialise bexobrutideg (also designated as NX-5948), Nurix’s investigational targeted protein degrader designed to eliminate Bruton’s Tyrosine Kinase (BTK). The alliance encompasses a comprehensive clinical development blueprint that establishes a cross-therapeutic architecture spanning malignant haematology, immunology, and neurology.
The documented financial tranches, pharmacological properties of the asset, and global commercial market projections include:
-
Financial Terms, Cost-Splitting, and Transaction Timeline:
-
Upfront and Milestone Tranches: Under the structural covenants of the deal, Nurix will secure an immediate upfront cash payment of USD 700 million. Concurrently, the biotech firm remains eligible to capture subsequent development, regulatory, and commercial sales milestone payments, bringing the potential aggregate deal value up to USD 2.3 billion.
-
Operational Expense Share: Global development costs will be shared systematically between the partners, with Nurix absorbing 40% and Roche financing 60% of the financial burden. For the United States jurisdiction, the entities will split all commercialisation profits and losses equally (50/50) and will co-commercialise the asset across all validated indications. Outside the United States, Roche will assume absolute commercial responsibility, while Nurix yields tiered royalty tranches ranging from the low- to high-teens on net product sales.
-
Regulatory Clearance Targets: The final closing of the transaction remains subject to standard customary conditions, including the statutory expiration or early termination of the waiting period dictated under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Corporate management expects the transaction to officially close during the third quarter of 2026.
-
-
Technical Specifications and Clinical Scope of Bexobrutideg:
-
Targeted Degradation Mechanism: Unlike conventional small-molecule BTK inhibitors that merely block downstream kinase activity, bexobrutideg is an investigational, orally bioavailable, and brain-penetrant molecule that harnesses the human body’s intrinsic protein disposal machinery. It selectively eliminates the physical BTK protein from cells, completely removing both its enzymatic kinase activity and its internal scaffolding function. This structural eradication enables the compound to potentially overcome treatment-emergent resistance mutations that limit standard-of-care inhibitors.
-
Clinical Evaluation Roadmap: The joint ventures plan to launch a definitive Phase 3 clinical trial program in the summer of 2026, evaluating the asset as a second-line therapeutic option for chronic lymphocytic leukaemia (CLL).
-
Cross-Therapeutic Adaptations: Because BTK serves as a central signalling node driving autoimmune and neurodegenerative cascades, the partners are expanding bexobrutideg’s utility into immunology for chronic spontaneous urticaria (CSU) and into neurology for multiple sclerosis (MS)—a debilitating pathology currently impacting nearly 3 million individuals globally.
-
-
Market Capacity Forecasts and Expansion Metrics:
-
BTK-targeting interventions constitute the frontline class within the rapidly growing non-Hodgkin lymphoma (NHL) and CLL commercial landscapes. This combined market is statistically projected to reach a valuation of $41 billion by 2031, with legacy BTK inhibitors expected to command the leading market segment at approximately $19 billion.
-
The expansion is highly visible within the specific CLL sector, which is forecasted to grow from a $12 billion baseline in 2024 to over $16 billion by 2035. The strategic alliance empowers Nurix to rapidly evaluate combination regimens combining bexobrutideg with successful B-cell malignancy drugs from Roche’s established global portfolio.
-
Source: https://www.roche.com/media/releases/med-cor-2026-06-08